Ex Vivo Intestinal Organoid Models: Current State-of-the-Art and Challenges in Disease Modelling and Therapeutic...

Area of Science:

• Oncology
• Cell Biology
• Biomedical Engineering

Background:

• Colorectal cancer (CRC) remains a leading cause of cancer mortality globally, necessitating improved research models.
• Traditional two-dimensional (2D) cell line cultures lack the complexity and physiological relevance of in vivo environments.
• Limitations of 2D models include reduced epithelial diversity, differentiation, mucus production, and absence of microbial and mechanical interactions.

Purpose of the Study:

• To evaluate the applicability of advanced in vitro culturing technologies, specifically organoid systems, for colorectal cancer research.
• To assess the potential of organoids in testing chemotherapeutic drug sensitivity and efficacy.
• To discuss the future role of organoid technology in advancing colorectal cancer disease modeling and personalized medicine.

Main Methods:

• Review and discussion of advanced culturing technologies, including organoid systems and microfluidic organ-on-a-chip models.
• Comparison of these advanced models with traditional 2D cell cultures and established ex vivo models (patient-derived explants, xenografts).
• Analysis of the physiological relevance and complexity offered by organoid systems for CRC modeling.

Main Results:

• Organoid systems provide a more holistic and physiologically relevant in vitro model for colorectal cancer compared to 2D cultures.
• These advanced models show promise for more accurate assessment of chemotherapeutic drug sensitivity and efficacy.
• Organoid technology addresses key limitations of traditional models, offering improved insights into CRC aetiology and treatment response.

Conclusions:

• Organoid systems represent a significant advancement in colorectal cancer modeling, offering greater physiological relevance.
• These models hold potential for improving drug sensitivity testing and facilitating personalized medicine approaches for CRC patients.
• Further development and challenges in organoid technology are critical for realizing its full potential in accurate disease modeling and tailored therapies.